Association of tuberous sclerosis gene 1/2 mutations with the progression of hepatocellular carcinoma and prognosis
DOI:10.3969/j.issn.1001-5256.2021.01.017
- VernacularTitle:结节性硬化基因1/2突变与肝细胞癌进展及预后的关系
- Author:
Yong ZHANG
1
;
Zhengfa MAO
Author Information
1. Department of General Surgery, The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 225500, China
- Publication Type:Research Article
- Keywords:
Carcinoma, Hepatocellular;
Tuberous Sclerosis;
Gene;
Mutation
- From:
Journal of Clinical Hepatology
2021;37(1):84-88
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the association of tuberous sclerosis gene 1/2 (TSC1/2) mutation with disease severity and prognosis in patients with hepatocellular carcinoma (HCC), and to provide a feasible basis for the diagnosis and treatment of HCC. MethodsA total of 492 patients with HCC who were admitted to The Affiliated Hospital of Jiangsu University from January 2012 to January 2020 were enrolled, among whom 59 had TSC1/2 mutations (20 with TSC1 mutations, 41 with TSC2 mutations, and 2 had both TSC1 and TSC2 mutations). The clinical features of patients with TSC1/2 mutations were analyzed, and the association of TSC1/2 mutations with the clinical stage of HCC was analyzed. The 35 patients in the mutation group and 35 in the non-mutation group were followed up for 3 years to observe the effect of TSC1/2 mutations on the prognosis of HCC. The chi-square test was used for comparison of categorical data between groups; the Kruskal-Wallis H test was used for comparison of ranked data between groups; a multivariate logistic regression analysis was used to investigate association; the Kaplan-Meier survival analysis was used to analyze follow-up data. ResultsFor the 492 patients with HCC, the overall TSC1/2 mutation rate was 11.99%. There were no significant differences in sex, age, Child score, and tumor size between the TSC1/TSC2 mutation group and the non-mutation group (all P＞0.05), while there were significant differences in tumor number, extrahepatic metastasis, and PS score between the two groups (all P＜0.05). The logistic regression analysis showed that TSC1/TSC2 gene mutation was positively correlated with the severity of HCC (odds ratio=1.706, P＜0.05). The follow-up results showed that the TSC1/2 mutation group had a significantly lower survival rate than the non-mutation group, and there was a significant difference in 3-year mortality rate between the TSC1/2 mutation group and the non-mutation group (60.3% vs 38.6%, χ2=3.923,P＜0.05). ConclusionTSC1/TSC2 gene mutation may predict the malignant progression of HCC in the early stage, and patients with TSC1/2 mutation tend to have poor prognosis. Targeted drug therapy for gene mutations may have a certain effect in delaying the progression of HCC.
